Table 2. Analysis of characteristics associated with HIV-DNA detection in the genital tract of women included in the study group.

		Undetectable	Detectable
		HIV-DNA in vagina	HIV-DNA in vagina	P value	P value
		(n = 49)	(n = 29)	(univ.)	(multiv.)
Age, years		40	38,0	0.18
		[35]-[52]	[34]-[44]
Ethnicity, n				0.08
	Sub-Saharan African	34	21
	European	14	5
	Other	1	3
Heterosexual HIV transmission, n (%)		45 (92)	26 (90)	0.6
CDC staging, n				0.009
	A	37	12
	B	7	8
	C	5	9		0.006
Co-infection, n				0.3
	none	42	23
	HBV	2	4
	HCV	5	2
Lowest CD4+ T cells, /µL		18	12	0.005
		[12]-[26]	[8]-[16]
Highest plasma HIV-RNA, log/mL		4.9	5.4	0.06
		[4.6-5.4]	[4.8-5.7]
Time from HIV diagnosis to treatment, y		0.4	0.5	0.9
		[0.1-3]	[0.1-3.1]
CD4+ T cell count, /µL		709	613	0.15
		[496-894]	[408-800]
% CD4+ T cells		36	30	0.009
		[29]-[41]	[25]-[37]
CD4+/CD8+ ratio		1	0.7	0.02
		[0.7-1.4]	[0.6-1.1]
Residual viremia, n (%)		11 (22)	12 (41)	0.13	0.04
HIV-DNA in blood, log/106 PBMCs		2.7	2.8	0.13
		[2.3-3]	[2.5-3.1]
Time with plasma HIV-RNA <50 cp/mL, mo		48	36	0.17
		[23-72]	[16-65]
cART regimens, n				0.5
	3 NRTIs	3	1
	2 NRTIs + 1 NNRTI	20	11
	2 NRTIs + 1 PI	24	14
	2 NRTIs + 1 II	1	3
Vaginal colonization, n (%)		12 (24)	10 (34)	0.5
White blood cells/field, n		40	10	0.08
		[0-400]	[0-50]
Vaginal cells/field, n		100	70	0.3
		[43-188]	[43-100]
median [IQR]

Abbreviations : HBV: hepatitis B virus; HCV: hepatitis C virus; II: integrase inhibitor; NRTI: nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI: non nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.